Internal Medicine, Medical Oncology · Laredo, TX
NPI
1881845253
Since 2008
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
3
Medicare group memberships
Hospitals
2
Hospital affiliations
1710 E. Saunders St. Suite A 140
Laredo, TX, 78041
Phone (956) 796-3580
Groups this clinician bills Medicare through
Medicare paid, 2024
$170K
2,281 services
Medicare patients, 2024
423
Average age 75
Drug cost, 2024
$16.6M
4,218 prescriptions
Company payments, 2025
$3,075
From 32 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Mohsen Ghadimi-Mahani was code 99214 (office e&m - established), 881 times for 239 patients. In total Mohsen Ghadimi-Mahani billed 2,281 services in 16 codes, and Medicare paid $170K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-09-16.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 881 | 239 | $84.98 | $75K |
| 99232 Hospital E&M - Subsequent | Facility | 757 | 157 | $59.58 | $45K |
| 99222 Hospital E&M - Initial | Facility | 276 | 193 | $96.24 | $27K |
| 99213 Office E&M - Established | Office | 162 | 108 | $64.53 | $10K |
| 99231 Hospital E&M - Subsequent | Facility | 73 | 32 | $38.63 | $2,820 |
| 99204 Office E&M - New | Office | 39 | 39 | $128.31 | $5,004 |
| 99212 Office E&M - Established | Office | 25 | 20 | $30.24 | $756 |
| 99441 Telephone Services | Office | 19 | 15 | $43.82 | $833 |
By year: 2022 $215K for 2,905 services; 2023 $206K for 2,758 services; 2024 $170K for 2,281 services.
Medicare prescription drug claims, 2024
In 2024, the drug Mohsen Ghadimi-Mahani prescribed most often to Medicare patients was Anastrozole, with 393 prescriptions and refills. In total Mohsen Ghadimi-Mahani wrote 4,218 Medicare prescriptions that cost $16.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 393 | 590 | 66 | $3,638 |
| Ondansetron Hcl Generic | 134 | 135 | 95 | $3,476 |
| Levothyroxine Sodium Generic | 127 | 172 | 28 | $497 |
| Revlimid Lenalidomide | 126 | 126 | 21 | $2.1M |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 123 | 123 | 42 | $3,845 |
| Erleada Apalutamide | 123 | 135 | 19 | $1.7M |
| Prednisone Generic | 102 | 108 | 30 | $283 |
| Letrozole Generic | 92 | 126 | 15 | $1,355 |
| Hydroxyurea Generic | 83 | 92 | 13 | $1,442 |
| Potassium Chloride Generic | 79 | 103 | 26 | $727 |
| Eliquis Apixaban | 77 | 84 | 22 | $46K |
| Pantoprazole Sodium Generic | 77 | 107 | 31 | $501 |
| Gabapentin Generic | 65 | 65 | 22 | $429 |
| Dexamethasone Generic | 62 | 66 | 22 | $1,139 |
| Verzenio Abemaciclib | 61 | 61 | Under 11 | $957K |
Brand drugs: - claims; generic drugs: 3,055 claims; opioid claims: 240.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Mohsen Ghadimi-Mahani $3,075 ($3,075 in general payments such as food, travel and fees) from 32 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $408.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 14 | $408 |
| Pfizer Inc. PFE | 18 | $278 |
| Janssen Biotech, Inc. JNJ | 11 | $269 |
| Merck Sharp & Dohme LLC MRK | 11 | $253 |
| Stemline Therapeutics Inc. | 4 | $188 |
| Gilead Sciences, Inc. GILD | 6 | $186 |
| Celgene Corporation BMY | 8 | $162 |
| GlaxoSmithKline, LLC. GSK | 3 | $149 |
| Caris MPI, Inc. | 4 | $149 |
| Medtronic, Inc. MDT | 2 | $147 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.